Jiangsu Aidea Pharmaceutical Group Co., Ltd. Class A
SSSE:68848813.70
CNY
-0.40
(-2.84%)
ISIN
CNE1000041S6
Return %
Stock
S&P 500
1Y
-7.24
14.20
3Y
19.23
81.12
5Y
-12.40
68.34
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Quarterly Revenue
CNY
•
in mil. unless spec.Quarterly Earnings Per Share
CNY
•
in mil. unless spec.Quarterly Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Jie Zhang
- Full Time Employees
- 735
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- No. 2 Liuzhuang Road Yangzhou JS China 225008
- IPO Date
- Jul 20, 2020
- Website
- aidea.com.cn
- Similar Companies
- Business
- Jiangsu Aidea Pharmaceutical Co., Ltd. Jiangsu Aidea Pharmaceutical Co., Ltd. (688488.SS) is a China-based biopharmaceutical company focused on the research, development, production, and commercialization of innovative chemical medicines and human-sourced protein products, primarily targeting anti-virus, anti-inflammatory, and anti-tumor therapeutic areas. Founded on December 15, 2009, and headquartered in Yangzhou, Jiangsu Province, the company operates mainly in mainland China with expanding international collaborations, particularly in Africa; its core offerings include anti-HIV innovative drugs such as Ainuovirine Tablets (the first original oral new drug for HIV-1 treatment in China, approved in June 2021), Ainuomiti Tablets (a three-in-one single-tablet regimen combining Ainuovirine, lamivudine, and tenofovir disoproxil fumarate, approved in December 2022 and expanded with a new indication in October 2024 for both treatment-naïve and virologically-suppressed HIV-1 patients), and an advancing pipeline of 14 products including eight national Class 1 new drugs like the integrase inhibitor ACC017 (Phase Ib/IIa clinical trials launched in August 2024); human urinary protein products derived from proprietary online adsorption technology using high-efficiency resin, encompassing crude/intermediate forms and formulations of ulinastatin (urinary trypsin inhibitor), urokinase, human urinary kallidinogenase, and related APIs; and generic formulations such as exclusive Sennae Folium Granules for constipation relief and Bacillus Cereus Tablets (Changfukang®) for intestinal disorders including diarrhea. The company listed on the Shanghai Stock Exchange STAR Market on July 20, 2020, leveraging its expertise in resin adsorption processes to become a leading supplier of human-sourced proteins in China while building a comprehensive anti-HIV portfolio to address unmet clinical needs. Recent developments include the acquisition of control rights (31.161% stake) in Nanjing Nanda Pharmaceutical Co., Ltd. in 2024 to integrate human urine-derived protein raw materials and formulations, solidifying a dual-engine growth strategy; approval and commercial production launch of Ainuovirine API in June 2024; opening of wholly-owned subsidiary Chengdu Aidea Pharma Tech Co., Ltd. in January 2024 to advance ACC017 and combination therapies; strategic cooperation agreements signed on September 4, 2024, with China-Africa Development Fund, PharmaBlock Sciences, and Nigeria's Fidson Healthcare Plc for a new pharmaceutical plant and West African market expansion; inclusion of Ainuovirine and Ainuomiti in the Chinese Guidelines for Diagnosis and Treatment of HIV/AIDS (2024 Edition) with Ainuomiti as an A1 preferred initial regimen; publication of Phase III SPRINT study data on Ainuomiti in The Lancet Regional Health–Western Pacific in July 2024; multiple real-world studies and presentations at international AIDS conferences (APACC, AIDS 2024, IDWeek, HIV Glasgow); receipt of the Second Prize of the 2023 Jiangsu Province Science and Technology Award for Ainuovirine development; and recognition as a national "Little Giants" enterprise and high-tech enterprise in 2024.